Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

NNASDAQ:TNXP
2.88
USD
-0.13
(-4.32%)
-11.95EPS
186.52MMarket Cap
Mar 15Next Earn

Total Valuation

USD

As of September 30, 2026, Tonix Pharmaceuticals Holding Corp. carries a market capitalization of 186.52M, placing it among publicly traded companies globally. Its enterprise value stands at 24.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap186.52M
Enterprise Value24.98M

Important Dates

Tonix Pharmaceuticals Holding Corp.'s next confirmed earnings release is scheduled for March 15, 2027.

Earnings Date3/15/2027

Share Statistics

As of September 30, 2026, Tonix Pharmaceuticals Holding Corp. has 19.15M shares outstanding.

Shares Outstanding19.15M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.43, and the price-to-book ratio stands at 0.94.

PS Ratio3.43
PB Ratio0.94
P/TBV Ratio0.94
P/FCF Ratio-0.87
P/OCF Ratio-0.89

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 0.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 24.98M versus a market cap of 186.52M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.58

Financial Position

As of September 30, 2026, Tonix Pharmaceuticals Holding Corp. maintains a current ratio of 4.57, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Current Ratio4.57
Quick Ratio4.33
Debt / Equity0.63
Debt / EBITDA-0.01

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Tonix Pharmaceuticals Holding Corp. posted a negative return on equity (ROE) of -84.06, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -73.15, reflecting losses generated across the asset base. The company generates approximately 303,140.85 in revenue per employee across its workforce of 142.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.90 indicates how many times Tonix Pharmaceuticals Holding Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-84.06
Return on Assets (ROA)-73.15
Revenue Per Employee303,140.85
Employee Count142.00
Inventory Turnover0.90

Stock Price Statistics

USD

As of the close on November 16, 2026, Tonix Pharmaceuticals Holding Corp.'s stock has declined approximately 81.89% over the past 52 weeks. The 50-day moving average sits at 7.51, while the 200-day moving average is 11.72.

52-Week Price Change-81.89%
50-Day Moving Average7.51
200-Day Moving Average11.72

Income Statement

USD

Over the twelve months ended September 30, 2026, Tonix Pharmaceuticals Holding Corp. generated 43.05M in revenue and converted that into -180.98M in net income, yielding earnings per share of -11.95. EBITDA reached -185.48M, while operating income came in at -186.45M.

Revenue43.05M
Gross Profit38.46M
Operating Income-186.45M
Pretax Income-180.98M
Net Income-180.98M
EBITDA-185.48M
EBIT-187.79M
Earnings Per Share (EPS)-11.95

Balance Sheet

USD

As of September 30, 2026, Tonix Pharmaceuticals Holding Corp. holds 162.79M in cash and equivalents against 1.25M in total debt, resulting in a net debt position of -162.79M. Total book value stands at 199.49M, with working capital of 150.11M providing operational flexibility.

Cash & Cash Equivalents162.79M
Total Debt1.25M
Net Debt-162.79M
Equity (Book Value)199.49M
Book Value Per Share10.42
Working Capital150.11M

Cash Flow

USD

Tonix Pharmaceuticals Holding Corp. produced -165.28M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -4.76M in capital expenditures, free cash flow totaled -170.04M - equivalent to -11.23 per share.

Operating Cash Flow-165.28M
Capital Expenditures-4.76M
Free Cash Flow-170.04M
FCF Per Share-11.23

Margins

Over the twelve months ended September 30, 2026, Tonix Pharmaceuticals Holding Corp. posted a gross margin of 89.33, reflecting its pricing power and cost economics. The operating margin of -433.15 and net profit margin of -420.45 provide insight into operational efficiency.

Gross Margin89.33
Operating Margin-433.15
Pretax Margin-420.45
Profit Margin-420.45
EBITDA Margin-430.90

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -115.27: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -75.67, meaning Tonix Pharmaceuticals Holding Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-75.67
FCF Yield-115.27

Stock Splits

Tonix Pharmaceuticals Holding Corp.'s most recent stock split took place on February 5, 2025 with a 100:1 split ratio.

Last Split Date2/5/2025
Split Ratio100:1

Scores

As of September 30, 2026, Tonix Pharmaceuticals Holding Corp. has an Altman Z-Score of -4.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-4.72